Company intelligence / Profile preview
3D Medicines Inc.
Qingdao, Shandong, China3d-medicines.com ↗
- Ownership
- Public · 1244.HK
- Employees
- ~191
- Development stage
- Other
01
Overview
The company’s lead product Envafolimab—a subcutaneous anti-PD-L1 antibody—has been commercialized for MSI-H/dMMR advanced solid tumors. The pipeline includes late-stage assets such as peptide vaccines and novel receptor antagonists targeting various solid tumors. Several programs are in pivotal or registration trials across multiple oncology indications.
- Therapeutic areas
- Oncology
- Modalities
- Monoclonal antibodies (mAbs)Small moleculesPeptide cancer vaccines
- Industry
- Biotech
02
Drug pipeline
14 assets13 more assets in the full pipeline.
03
Partnerships
Commercialization through external production/sales partnerships mentioned but specific partners not listed by name.License-in assets also referenced but no partner names provided.
04
Financials
- Market cap
- $81.7M
- Total revenue
- $53.4M
- Enterprise value
- $48.2M
Beyond the preview
Go deeper on 3D Medicines Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 3D Medicines Inc..